Santana Machado T, Cerini C, Burtey S
Toxins (Basel). 2019; 11(4).
PMID: 30959953
PMC: 6521271.
DOI: 10.3390/toxins11040209.
Chapron A, Shen D, Kestenbaum B, Robinson-Cohen C, Himmelfarb J, Yeung C
Clin Transl Sci. 2017; 10(5):395-403.
PMID: 28675584
PMC: 5593164.
DOI: 10.1111/cts.12481.
Nolin T
Semin Dial. 2015; 28(4):325-9.
PMID: 25855244
PMC: 4496305.
DOI: 10.1111/sdi.12374.
Mawer G, Ahmad R, Dobbs S, McGough J, Lucas S, Tooth J
Br J Clin Pharmacol. 2012; 1(1):45-50.
PMID: 22454868
PMC: 1402410.
DOI: 10.1111/j.1365-2125.1974.tb00205.x.
Reidenberg M
J Clin Pharmacol. 2012; 52(1 Suppl):7S-9S.
PMID: 22232758
PMC: 3923528.
DOI: 10.1177/0091270011413587.
Drug dosage in end-stage renal disease (ESRD) patients undergoing haemodialysis. A predictive study based on a microcomputer program.
Sanchez Burson J, Dominguez-Gil A
Clin Pharmacokinet. 1993; 25(3):243-57.
PMID: 8222463
DOI: 10.2165/00003088-199325030-00007.
The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites.
Hoffmann K, Regardh C, Aurell M, ERVIK M, Jordo L
Clin Pharmacokinet. 1980; 5(2):181-91.
PMID: 7363533
DOI: 10.2165/00003088-198005020-00005.
The pharmacokinetics of nortriptyline in patients with chronic renal failure.
Dawlilng S, Lynn K, Rosser R, Braithwaite R
Br J Clin Pharmacol. 1981; 12(1):39-45.
PMID: 7248140
PMC: 1401753.
DOI: 10.1111/j.1365-2125.1981.tb01852.x.
Pharmacokinetics of metioprim in normal subjects and patients with impaired renal function.
Vergin H, kaiser W, Kohler M, Strobel K, REUTTER F
Antimicrob Agents Chemother. 1983; 24(2):190-3.
PMID: 6638987
PMC: 185136.
DOI: 10.1128/AAC.24.2.190.
Formal theory of discrete drug dosing regimen adjustments.
JANKU I
Eur J Clin Pharmacol. 1983; 25(1):123-30.
PMID: 6617714
DOI: 10.1007/BF00544028.
Differences in kinetic properties of drugs: implications as to the selection of a particular drug for use in patients with renal failure with special emphasis on antibiotics and beta-adrenoceptor blocking agents.
Fabre J, FOX H, Dayer P, Balant L
Clin Pharmacokinet. 1980; 5(5):441-64.
PMID: 6105934
DOI: 10.2165/00003088-198005050-00003.
Translation of pharmacokinetics to clinical medicine.
DETTLI L
J Pharmacokinet Biopharm. 1973; 1(5):403-18.
PMID: 4787617
DOI: 10.1007/BF01059665.
Proceedings: Digoxin dosage in patients with impaired kidney function.
DETTLI L, Ohnhaus E, Spring P
Br J Pharmacol. 1972; 44(2):373P.
PMID: 4668631
PMC: 1666095.
Cephalexin: a review of its antibacterial, pharmacological and therapeutic properties.
Speight T, Brogden R, Avery G
Drugs. 1972; 3(1):9-78.
PMID: 4559812
DOI: 10.2165/00003495-197203010-00002.
Pitfalls of pharmacokinetic dosage guidelines in renal insufficiency.
Turnheim K
Eur J Clin Pharmacol. 1991; 40(1):87-93.
PMID: 2060552
DOI: 10.1007/BF00315145.
Individualising gentamicin dosage regimens. A comparative review of selected models, data fitting methods and monitoring strategies.
Jelliffe R, Iglesias T, Hurst A, Foo K, Rodriguez J
Clin Pharmacokinet. 1991; 21(6):461-78.
PMID: 1782740
DOI: 10.2165/00003088-199121060-00006.
Pharmacokinetics in the elderly.
Triggs E, Nation R, Long A, ASHLEY J
Eur J Clin Pharmacol. 1975; 8(1):55-62.
PMID: 1233203
DOI: 10.1007/BF00616415.
Treatment with sisomicin of complicated urinary tract infections in patients with varying degrees of renal function impairment, pharmacokinetics and dosage adjustment.
Mosegaard A, Welling P, Tse F, Madsen P
Infection. 1975; 3(3):143-7.
PMID: 1223005
DOI: 10.1007/BF01641336.
Elimination kinetics of sulfadiazine in patients with normal and impaired renal function.
Ohnhaus E, Spring P
J Pharmacokinet Biopharm. 1975; 3(3):171-9.
PMID: 1159621
DOI: 10.1007/BF01067906.
Drug dosage in renal disease.
DETTLI L
Clin Pharmacokinet. 1976; 1(2):126-34.
PMID: 797495
DOI: 10.2165/00003088-197601020-00004.
